General Info

Dr. C. Ola Landgren, is a board-certified hematologist/oncologist who specializes in multiple myeloma, smoldering myeloma, monoclonal gammopathy of undetermined significance, and related plasma cell disorders. His research approaches include detailed genomic characterization of tumor cells and cells in the bone marrow microenvironment, partnered with novel drug development, and advanced methods to rule out minimal residual disease (MRD). Dr. Landgren has developed several novel strategies designed to identify MRD detection post-therapy. He leads the clinical and research operations as well as the development of the Myeloma Program at Sylvester and his career highlights include:? Strong track-record in drug development? Served as a principal investigator for a large number of clinical trials? Principal Investigator for the Myeloma Genomic Research Laboratory at Sylvester Comprehensive Cancer Center? Designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease to multiple myeloma? Designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease to multiple myeloma